Valuation: Serina Therapeutics, Inc.

Market Cap 42.74M 37.05M 34.73M 31.67M 59.59M 4.08B 60.54M 409M 160M 2.04B 160M 157M 6.81B P/E 2026 *
-1.46x
P/E 2027 * -1.82x
Enterprise Value 42.74M 37.05M 34.73M 31.67M 59.59M 4.08B 60.54M 409M 160M 2.04B 160M 157M 6.81B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
14.04%
Yield 2026 *
-
Yield 2027 * -
1 day+1.06%
1 week+21.28%
Current month+42.50%
1 month+39.02%
3 months+82.69%
6 months+55.74%
Current year+48.98%
1 week 2.31
Extreme 2.31
2.86
1 month 1.93
Extreme 1.9301
2.86
Current year 1.22
Extreme 1.22
4.08
1 year 1.22
Extreme 1.22
7.92
3 years 1.22
Extreme 1.22
19.93
5 years 1.22
Extreme 1.22
19.93
10 years 1.22
Extreme 1.22
19.93
Date Insider Type Main position Quantity % Market Cap.
7/22/26 Free

Director

30,500 0.2034%
7/7/26 Buy

Director

1,000 0.0067%
5/19/26 Buy

Director

12,183 0.0989%
Change 5-day change 1-year change 3-year change Capi.($)
+1.06%+21.28%-46.88% - 42.29M
+2.07%+13.76%+65.44%+106.53% 70.1B
-0.87%+0.08%+36.96%+65.91% 54.93B
-4.50%-4.69%+2.82%+463.22% 28.89B
+0.31%-0.31%+48.35%+7.45% 23.9B
-0.67%+1.02%-18.32%-13.84% 23.3B
+0.35%+12.02%+257.19%+466.50% 18.41B
-0.59%+7.88%+40.87%-20.56% 18.77B
-0.48%-3.24%+20.39%+615.07% 16.1B
+0.46%-3.05%+31.49%+135.18% 12.48B
Average -0.34%+6.88%+43.83%+202.83% 26.69B
Weighted average by Cap. -0.22%+3.98%+51.13%+165.30%

Financials

2026 *2027 *
Net sales - -
Net income -26.61M -23.07M -21.62M -19.72M -37.1M -2.54B -37.69M -255M -99.4M -1.27B -99.91M -97.75M -4.24B -27.18M -23.56M -22.09M -20.14M -37.89M -2.59B -38.5M -260M -102M -1.3B -102M -99.83M -4.33B
Net Debt - -
Logo Serina Therapeutics, Inc.
Serina Therapeutics Inc. is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. The Company's POZ Platform provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). Its proprietary POZ technology is based on a synthetic, water soluble, low viscosity polymer called poly(2-oxazoline). Its POZ technology is engineered to provide greater control in drug loading and more precision in the rate of release of attached drugs delivered via subcutaneous injection. SER-252 is the Company’s lead candidate for advanced Parkinson’s disease. SER-252 is an investigational apomorphine therapy developed with its POZ platform and designed to provide continuous dopaminergic stimulation.
Employees
-
Date Price Change Volume
26-08-13 US$2.850 +1.06% 54,688
26-08-12 US$2.820 +1.44% 108,601
26-08-11 US$2.780 +4.12% 118,071
26-08-10 US$2.670 +11.25% 139,236
26-08-07 US$2.400 +2.13% 26,588
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.850USD
Average target price
9.500USD
Spread / Average Target
+233.33%

Quarterly revenue - Rate of surprise